Critical Contrast: Cannlabs (OTCMKTS:CANL) vs. IceCure Medical (NASDAQ:ICCM)

Cannlabs (OTCMKTS:CANL) and IceCure Medical (NASDAQ:ICCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Insider & Institutional Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Cannlabs and IceCure Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cannlabs	N/A	N/A	N/A	N/A	N/A
IceCure Medical	$3.29 million	13.57	-$15.32 million	($0.26)	-2.50

Cannlabs has higher earnings, but lower revenue than IceCure Medical.

Volatility and Risk

Cannlabs has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.

Profitability

This table compares Cannlabs and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cannlabs	N/A	N/A	N/A
IceCure Medical	-513.95%	-243.68%	-123.94%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cannlabs and IceCure Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cannlabs	0	0	0	0	0.00
IceCure Medical	1	1	2	0	2.25

IceCure Medical has a consensus target price of $2.64, suggesting a potential upside of 305.38%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Cannlabs.

Summary

IceCure Medical beats Cannlabs on 6 of the 10 factors compared between the two stocks.

About Cannlabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.